Novo Nordisk announced the availability of Wegovy tablets, the first oral GLP-1 receptor agonist for weight loss and CV risk ...

For patients with hypertension, initiating treatment with an ARB is associated with the best long-term class persistence.

In 2025, the number of all students enrolled in medical school reached 100,723 — a significant milestone for the future of health care. After a slight dip in recent years, overall applications rose ...

Early intensive BP control significantly reduces cardiovascular risk in older patients compared with delayed initiation of treatment.

Management of mitochondrial-related heart disease relies on multidisciplinary care and symptom control, as targeted gene-editing therapies are limited.

Reaching prediabetes remission is linked to a decades-long benefit, with risk for cardiovascular death or hospitalization for HF cut in half.

Carotid stenosis severity serves as a predictor for cognitive impairment independent of white matter lesions and traditional vascular risk factors.

The FDA is weighing a change that could make warning labels on dietary supplements appear less often on packaging.

Incidence of death or BPD does not differ with expectant management versus active treatment for preterm infants with protocol-defined PDA.

Ketamine for anesthesia does not lower in-hospital death by day 28 compared with etomidate among critically ill adults undergoing tracheal intubation.

The FDA has approved Wegovy (semaglutide) tablets, the first oral GLP-1 receptor agonist for the treatment of obesity.

The CDC has rescinded its long-standing advice on universal hepatitis B vaccination of newborns within 24 hours of birth.